Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta to Collaborate with Unnamed Pharma on microRNA-based Alzheimer's Dx


NEW YORK (GenomeWeb) – Rosetta Genomics this week announced that it has signed a deal with an undisclosed global pharmaceutical firm to develop a microRNA-based diagnostic for the early detection of Alzheimer's disease.

Under the deal, Rosetta will provide the pharma with miRNA profiling services and expertise. Additional terms of the arrangement were not disclosed.